No Link Between Blood Pressure Drugs and Cancer Found: FDA

|
Staff Writers

Add Your Comments

Federal drug safety experts say they can find no link between cancer and a popular class of blood pressure control medications, which include Benicar, Atacand, Avapro, Cozaar, Diovan, Micardis and Tevetan. 

The FDA launched a drug safety review of the blood pressure control drugs, known as angiotensin receptor blockers (ARBs), in July 2010, after some data suggested the medications may increase the risk of cancer.

Reviewers who looked at all the available data determined that the drugs do not increase the risk of cancer, given the data currently available. The agency’s findings were announced on Thursday in an ARB drug safety communication.

Do You Know about…

Spinal Cord Stimulator lawsuits

Spinal cord stimulator lawsuits are being investigated for individuals who suffered unnecessary shocks, burns or other problems, often resulting in the need for additional surgery to remove the SCS.

Learn More
SEE IF YOU QUALIFY FOR COMPENSATION
Spinal-Cord-Stimulation-Lawsuit
Spinal-Cord-Stimulation-Lawsuit

Do You Know About…

Spinal Cord Stimulator lawsuits

Spinal cord stimulator lawsuits are being investigated for individuals who suffered unnecessary shocks, burns or other problems, often resulting in the need for additional surgery to remove the SCS.

Learn More
SEE IF YOU QUALIFY FOR COMPENSATION

As part of the safety review, the FDA conducted a trial-level meta-analysis of 31 clinical trials where patients were given an ARB or non-ARB treatment. The trials included about 156,000 patients collectively.

The FDA recommends that patients do not stop taking ARB medication without first consulting a health care professional.

The FDA review was initiated after a study on side effects of Benicar published last year in the medical journal Lancet Oncology found that the use of ARBs was linked to a 1% increase in the risk a number of forms of cancer, including lung, prostate and breast cancer.

Benicar was already under investigation by the FDA due to two recent studies that suggest the drug can cause an increase in the risk of death due to heart problems in patients with type 2 diabetes. FDA officials are concerned that the side effects of Benicar may have played a factor in the cardiovascular deaths of 25 test subjects who participated in the two studies.

Tags: Atacand, Avapro, Benicar, Blood, Breast Cancer, Cozaar, Diabetes, Diovan, Micardis, Tevetan
Image Credit: |

More Benicar Lawsuit Stories

0 Comments

This field is for validation purposes and should be left unchanged.

Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

MORE TOP STORIES

Judge Clears Bard PowerPort Lawsuit for Trial, Rejecting Motion for Summary Judgment
A U.S. District Judge refused to dismiss a Bard PowerPort lawsuit just two weeks before it is supposed to go to trial, saying the manufacturer will have to convince a jury with their arguments and not him.
Dupixent Lawyers Seek Leadership Positions in MDL Over Cancer Risks
Plaintiffs propose that about a dozen attorneys be appointed to leadership positions in the growing Dupixent cancer litigation.
MORE ABOUT: DUPIXENT LAWSUIT
Lawyers Preparing 35 Suboxone Tooth Decay Lawsuits in Core Discovery Pool
Nearly three dozen Suboxone tooth decay lawsuits are being prepared for early test trials, involving the deposition of plaintiffs who say they suffered tooth loss as a result of using the opioid addiction treatment.